Eveliqure's effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries is supported by the Wellcome Trust

The Wellcome Trust Innovator Award of ~£500K complements the previously secured ~€11 million funding from public sources for the vaccine’s development (Horizon2020, Austrian Wirschaftservice and Austrian Research Promotion Agency, FFG).